Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276708 | 0.86 | CRHR1 (0.38) | MAPTKMT2A | |
| SCHEMBL1179561 | 0.84 | MEN1 (0.42) | TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL27790943 | 0.82 | HDAC6 (0.40) | — | |
| SCHEMBL3280184 | 0.79 | HRH4 (0.31) | TSHR | |
| SCHEMBL1179224 | 0.78 | GAA (0.37) | KMT2ASMN1; SMN2 | |
| SCHEMBL1425034 | 0.76 | HCAR3 (0.39) | MAPTTSHRKMT2ASMN1; SMN2 | |
| SCHEMBL1178817 | 0.74 | NOS3 (0.34) | SMN1; SMN2 | |
| SCHEMBL1180186 | 0.73 | HCRTR1 (0.35) | — | |
| SCHEMBL1179131 | 0.72 | CYP1A2 (0.35) | MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL1179315 | 0.71 | GAA (0.33) | KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125797-B1 | AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-01-15 | — | — | EP | disclosed |
| US-8592460-B2 | Amino-pyridine derivatives as S1P1 /EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | disclosed |
| US-20100087417-A1 | AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-08 | — | — | US | disclosed |
| EP-2125797-A1 | AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008114157-A1 | AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087417-A1 | AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR4 | MAPT 3740/4885TSHR 1036/4885KMT2A 1916/4885 |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | TYMP, DPYD, ENTPD5 | MAPT 3786/4885TSHR 2962/4885KMT2A 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.